The Post-Finasteride Syndrome Foundation’s primary mission is to facilitate research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.
Adverse drug reaction reports worldwide
PFS research studies published
Known suicides worldwide
Doctors & researchers speaking out
Nations warning of PFS
February 20, 2020 Dear Friends: “Clinicians should be aware that men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.” That, according to new research by Michael S. Irwig, MD, attending endocrinologist at Beth Israel Deaconess Medical Center in Boston, […]
December 20, 2019 Dear Friends: France’s FDA-equivalent agency last week issued an Information Point and fact sheet for men currently taking finasteride for hair loss, or for those considering taking the drug for hair loss. “Developed in conjunction with concerned patient associations and health professionals, this fact sheet aims to reinforce patient information on the […]
October 21, 2019 Dear Friends: PFS awareness took an enormous leap forward today—over the Great Wall and into the Sleeping Giant. At the stroke of midnight, we unveiled a Mandarin Chinese version of our website so that speakers of the world’s second most popular language can learn all about the condition (known to them as […]
Sept. 16, 2019 Dear Friends: Dan Levine, an investigative journalist with the largest news agency in the Western world, last week published a 3,900-word investigative report headlined Court let Merck hide secrets about a popular drug’s risks. A year in the making, the Reuters story uncovered testimony by former Merck executives in the US Propecia […]
Aug. 17, 2019 Dear Friends: The Boot has begun kicking Propecia. Last week, Italian health and lifestyle magazine Starbene, which boasts a weekly circulation of 350,000, ran a story on PFS that begins: The entire world, including Italy, is experiencing a tragedy that requires our attention. It’s that of men, often young, who in hopes […]
Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.
An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use – insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.
—Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020
[A]t least 17 countries…have warned…of the potential for depression, sexual side effects, or both.
Emerging post-marketing reports of persistent depression and sexual side effects have led to growing concerns about the safety of 5α-reductase inhibitors and prompted product labeling changes in many regulatory jurisdictions. Since 2008, at least 17 countries including the United Kingdom and the United States have warned prescribers of the potential for depression, sexual side effects, or both with finasteride.
Two subjects—eight percent—committed suicide during or after the study.
While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during or after the study.
—Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia: Translational Andrology and Urology, April 2020
FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.
Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.
—FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000